Using a contingency table chi-square test, the results showed that there was a significantly higher proportion of patients with MON-ON developing symptoms within 6 weeks after COVID-19 compared to those with AQP4-ON (15/23 [65.2%] vs. 5/17 [29.4%]; p = 0.025). Here, AQP4 is linked to COVID-19.